Stock News

What’s Athersys Inc (NASDAQ:ATHX) Upside After This Short Interest Increase?

Athersys, Inc. (NASDAQ:ATHX) Logo

Investors sentiment increased to 2.42 in 2018 Q2. Its up 1.53, from 0.89 in 2018Q1. It improved, as 3 investors sold Athersys, Inc. shares while 16 reduced holdings. 15 funds opened positions while 31 raised stakes. 25.84 million shares or 11.94% more from 23.09 million shares in 2018Q1 were reported.
Moneta Grp Inc Investment Advisors Lc holds 0% in Athersys, Inc. (NASDAQ:ATHX) or 1,133 shares. Raymond James Financial Ser Advisors invested 0% in Athersys, Inc. (NASDAQ:ATHX). Ny State Common Retirement Fund has invested 0% in Athersys, Inc. (NASDAQ:ATHX). Morgan Stanley owns 316,548 shares for 0% of their portfolio. Ontario – Canada-based Manufacturers Life Ins The has invested 0% in Athersys, Inc. (NASDAQ:ATHX). Hudson Valley Advisors Adv holds 0.01% or 22,500 shares. Ancora Limited Liability Company invested 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX). Moreover, Natixis has 0% invested in Athersys, Inc. (NASDAQ:ATHX) for 40,000 shares. Personal holds 0% or 20,000 shares in its portfolio. American Grp reported 0% in Athersys, Inc. (NASDAQ:ATHX). Balyasny Asset Lc stated it has 16,545 shares or 0% of all its holdings. Cubist Systematic Strategies Ltd Limited Liability Company owns 31,700 shares. Millennium Ltd Limited Liability Company stated it has 457,667 shares. Lpl Limited Liability Co reported 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX). Rhumbline Advisers stated it has 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX).

Since June 14, 2018, it had 0 insider buys, and 5 sales for $216,786 activity. Another trade for 28,868 shares valued at $57,986 was sold by Campbell Laura K. Another trade for 15,000 shares valued at $28,707 was made by Harrington John J on Thursday, September 13.

The stock of Athersys Inc (NASDAQ:ATHX) registered an increase of 0.19% in short interest. ATHX’s total short interest was 11.07 million shares in November as published by FINRA. Its up 0.19% from 11.05M shares, reported previously. With 370,600 shares average volume, it will take short sellers 30 days to cover their ATHX’s short positions.

The stock decreased 2.09% or $0.04 during the last trading session, reaching $1.87. About 358,019 shares traded. Athersys, Inc. (NASDAQ:ATHX) has declined 3.52% since November 10, 2017 and is downtrending. It has underperformed by 19.14% the S&P500.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company has market cap of $259.15 million. The Company’s clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. It currently has negative earnings. The companyÂ’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers.

More news for Athersys, Inc. (NASDAQ:ATHX) were recently published by: Globenewswire.com, which released: “Market Trends Toward New Normal in Crown, Athersys, CSX, Magellan Health, Spectrum Brands, and MGIC …” on October 29, 2018. Globenewswire.com‘s article titled: “Athersys Reports Third Quarter 2018 Results” and published on November 06, 2018 is yet another important article.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*